BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2055 related articles for article (PubMed ID: 25625927)

  • 1. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines, electroporation and their applications in cancer treatment.
    Lee SH; Danishmalik SN; Sin JI
    Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
    Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
    Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy of cancer in elderly patients.
    Matzku S; Zöller M
    Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.
    Haupt K; Roggendorf M; Mann K
    Exp Biol Med (Maywood); 2002 Apr; 227(4):227-37. PubMed ID: 11910045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
    Pyzer AR; Avigan DE; Rosenblatt J
    Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
    Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
    Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
    Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
    Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
    Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.